Solvent/polymer solutions as suspension vehicles

Patent metadata

Field	Value
Publication number	US-9526763-B2
Application number	US-201514749178-A
Country	US
Kind code	B2
Filing date	Jun 24, 2015
Priority date	Feb 3, 2005
Publication date	Dec 27, 2016
Grant date	Dec 27, 2016

Abstract

A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.

First claim

What is claimed is:

1. A stable, nonaqueous suspension formulation, comprising:
a particle formulation comprising an active agent and at least one excipient, wherein:
the active agent comprises at least one of a peptide, a polypeptide, and a protein; and
the at least one excipient comprises methionine; and

a nonaqueous, single-phase vehicle consisting essentially of about 10% (w/w) to about 90% (w/w) polymer and about 90% (w/w) to about 10% (w/w) solvent, wherein:
the polymer is at least one of a polyester, a pyrrolidone, an ester of an unsaturated alcohol, an ether of an unsaturated alcohol, and a polyoxyethylenepolyoxypropylene block copolymer;
the solvent is at least one of lauryl alcohol, lauryl lactate, benzyl benzoate, benzyl alcohol, decanol, and ethyl hexyl lactate; and
the vehicle has a viscosity of about 1,000 poise to about 100,000 poise.

2. The suspension formulation of claim 1 , wherein the at least one excipient further comprises at least one of a buffer and a sugar.

3. The suspension formulation of claim 2 , wherein the at least one excipient comprises the sugar, wherein the sugar is at least one of sucrose and dextran.

4. The suspension formulation of claim 2 , wherein the at least one excipient comprises the buffer, wherein the buffer is at least one of citrate, phosphate, histidine, and succinate.

5. The suspension formulation of claim 2 , wherein the at least one excipient further comprises citrate and sucrose.

6. The suspension formulation of claim 1 , wherein the particle formulation is formed by at least one of lyophilization, spray-drying, and freeze-drying.

7. The suspension formulation of claim 1 , wherein the particle formulation is present in the suspension formulation in a range from about 0.1% (w/w) to about 50% (w/w).

8. The suspension formulation of claim 1 , wherein the particle formulation is present in the suspension formulation in a range from about 3% (w/w) to about 12% (w/w).

9. The suspension formulation of claim 1 , wherein the polymer is the pyrrolidone, and the pyrrolidone is polyvinylpyrrolidone (PVP).

10. The suspension formulation of claim 1 , wherein the nonaqueous, single-phase vehicle consists essentially of about 25% (w/w) to about 75% (w/w) polymer and about 75% (w/w) to about 25% (w/w) solvent.

11. The suspension formulation of claim 1 , wherein the nonaqueous, single-phase vehicle consists essentially of about 40% (w/w) to about 60% (w/w) polymer and about 60% (w/w) to about 40% (w/w) solvent.

12. The suspension formulation of claim 1 , wherein the nonaqueous, single-phase vehicle consists essentially of about 50% (w/w) polymer and about 50% (w/w) solvent.

13. The suspension formulation of claim 1 , wherein the nonaqueous, single-phase vehicle exhibits phase separation upon contact with an aqueous environment having less than about 10% water.

14. The suspension formulation of claim 1 , wherein the viscosity is about 5,000 poise to about 50,000 poise.

15. The suspension formulation of claim 1 , wherein the viscosity is about 10,000 poise to about 20,000 poise.

16. The suspension formulation of claim 1 , wherein the viscosity is measured at 37° C.

17. An implantable osmotic drug delivery device, comprising:
a reservoir containing a stable, nonaqueous suspension formulation, the suspension formulation comprising:
a particle formulation comprising an active agent and at least one excipient, wherein:
the active agent comprises at least one of a peptide, a polypeptide, and a protein; and
the at least one excipient comprises methionine; and

a nonaqueous, single-phase vehicle consisting essentially of about 10% (w/w) to about 90% (w/w) polymer and about 90% (w/w) to about 10% (w/w) solvent, wherein:
the polymer is at least one of a polyester, a pyrrolidone, an ester of an unsaturated alcohol, an ether of an unsaturated alcohol, and a polyoxyethylenepolyoxypropylene block copolymer;
the solvent is at least one of lauryl alcohol, lauryl lactate, benzyl alcohol, benzyl benzoate, decanol, and ethyl hexyl lactate; and
the vehicle has a viscosity of about 1,000 poise to about 100,000 poise; and

an orifice through which at least the active agent is delivered.

18. A method of making a stable, nonaqueous suspension formulation, the method comprising:
combining a polymer and a solvent under dry conditions to form a nonaqueous, single-phase vehicle consisting essentially of about 10% (w/w) to about 90% (w/w) polymer and about 90% (w/w) to about 10% (w/w) solvent, wherein:
the polymer is at least one of a polyester, a pyrrolidone, an ester of an unsaturated alcohol, an ether of an unsaturated alcohol, and a polyoxyethylenepolyoxypropylene block copolymer;
the solvent is at least one of lauryl alcohol, lauryl lactate, benzyl alcohol, benzyl benzoate, decanol, and ethyl hexyl lactate; and
the vehicle has a viscosity of about 1,000 poise to about 100,000 poise; and

adding a particle formulation comprising an active agent and at least one excipient to the vehicle to form the suspension formulation, wherein:
the active agent comprises at least one of a peptide, a polypeptide, and a protein; and
the at least one excipient comprises methionine.

19. The method of claim 18 , wherein a vacuum is applied during the combining to remove air bubbles from the vehicle, wherein the vacuum is about −5 Hg to about −30 Hg.

20. The method of claim 18 , wherein the polymer and the solvent are combined at an elevated temperature, wherein the elevated temperature is about 40° C. to about 70° C.

Assignees

• Intarcia Therapeutics Inc

Inventors

• Rohloff Catherine M
• Chen Guohua
• Luk Andrew S
• Ayer Rupal A
• Houston Paul R
• Desjardin Michael A
• Zamora Pauline
• Lam Stan

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61P13/12

  of the kidneys · CPC title